All In Biotech

Drug Trial Radar · NCT07895992

SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study

A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 in Combination With Bevacizumab Versus Sacituzumab Tirumotecan in Advanced or Metastatic Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

490

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2030

Sponsor

Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined bevacizumab versus Sacituzumab Tirumotecan in the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer

Conditions

  • Non-squamous Non-small Cell Lung Cancer

Interventions

  • SHR-A2009 + bevacizumabDrug

    SHR-A2009 + bevacizumab

  • Sacituzumab TirumotecanDrug

    Sacituzumab Tirumotecan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: about 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.